COVID-19 Vaccine - en | Covid19.go.id

About COVID-19 Vaccine

Lawan Covid19

What is Vaccination

Vaccination is the administration of vaccines in order to actively generate or increase a person's immunity against a disease, so that if one day they are exposed to the disease, they will not get sick or only experience mild illness and will not become a source of transmission.

COVID-19 vaccination services are carried out at Health Service Facilities owned by the Central Government, Provincial Governments, Regency/City Governments or owned by the public/private sector that meet the requirements, including:

  • Puskesmas, Puskesmas Pembantu
  • Clinic
  • Hospital and/or
  • Health Service Unit at the Port Health Office (KKP)
Or Check Here
District/City Health Offices and Puskesmas can also establish COVID-19 vaccination service posts. It is recommended that each target seek information in advance regarding the service schedule of each health service facility or vaccination service post.

How can Vaccines work in the body to protect us?

  • Vaccines are biological products that are given to a person to protect him or her from a debilitating, even life-threatening disease.
  • Vaccines will stimulate the formation of immunity against certain diseases in a person's body.
  • The body will remember the virus or disease-causing bacteria, recognize and know how to fight it.
Lawan Covid19

List of COVID-19 Vaccines Used in Indonesia

In the implementation of the COVID-19 vaccination program in Indonesia, the government strives for the availability of vaccines to be fulfilled for at least 208,265,720 of the population to achieve group immunity.

These vaccine procurement efforts are carried out through bilateral agreements and multilateral agreements such as the COVAX Facility with GAVI and WHO, or donations provided by friendly countries.

The Indonesian Food and Drug Administration has granted emergency use permits for 10 types of COVID-19 vaccines, namely Sinovac, AstraZeneca, Sinopharm, Moderna, Pfizer, Novavax, Sputnik-V, Janssen, Convidencia, and Zifivax.

Each of these types of vaccines has a mechanism for its own administration, from the number of doses, the interval of administration, to different vaccine platforms, namely inactivated virus, RNA-based, viral-vector, and protein sub-units.

*The vaccines provided are vaccines that have been confirmed to be safe and effective.

SINOVAC VACCINE
COVID-19 Vaccine (Vero Cell) Inactivated, CoronaVac® is an inactivated vaccine against COVID-19 that stimulates the immune system without the risk of causing disease. Once this inactivated vaccine comes into contact with the immune system, antibody production is stimulated, so the body is ready to respond to infection with live SARS-CoV-2. This vaccine contains an adjuvant (aluminum hydroxide), to strengthen the immune system response.
The ChAdOx1-S/nCoV-19 vaccine is a non-replicating adenovirus vector vaccine for COVID-19. The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cell to produce an S-antigen protein unique to SARS-CoV-2, so that the body can generate an immune response and store that information in memory immune cells. Efficacy in clinical trials in participants who received the full course of the vaccine (two doses) in the UK, Brazil, and South Africa regardless of the dose interval was 61%, with a median follow-up period of 80 days, but tends to be higher if this interval is longer. . Additional data from interim analyzes of clinical trials in the United States showed a vaccine efficacy of 76% against symptomatic SARS-CoV-2 infection.
Moderna's COVID-19 vaccine is a messenger RNA (mRNA) based vaccine for COVID-19. The host cell receives instructions from the mRNA to produce the unique S-antigen protein SARS-CoV-2, so that the body can generate an immune response and store that information in memory immune cells. Efficacy according to clinical trials in participants who received the full dose of this vaccine (two doses) and had an initial SARS-CoV-2 negative status was approximately 94% with a median follow-up period of nine weeks. All data reviewed support the conclusion that the known and potential benefits of the mRNA-1273 vaccine outweigh the known and potential risks.
The SARS-CoV-2 Vaccine (Vero Cell) is an inactivated vaccine against COVID-19 that stimulates the immune system without the risk of causing disease. Once this inactivated vaccine comes into contact with the immune system, antibody production is stimulated, so the body is ready to respond to infection with live SARS-CoV-2. This vaccine contains an adjuvant (aluminum hydroxide), to strengthen the immune system response. A large phase 3 clinical trial demonstrated that two doses at 21-day intervals had 79% efficacy against symptomatic SARS-CoV-2 infection 14 days or more after the second dose. These clinical trials are neither designed nor robust enough to demonstrate efficacy against severe disease.
COMIRNATY® is a messenger RNA (mRNA) based vaccine for COVID-19. The mRNA instructs the cell to produce an S-antigen protein (part of the spike protein) unique to SARS-CoV-2 to stimulate an immune response. In clinical trials, efficacy in participants with or without evidence of previous SARS-CoV-2 infection and who received the full dose of this vaccine (two doses) was estimated at 95% with a median follow-up period of two months.

Question and Answer

a. Bagi sasaran yang mengalami drop out dalam rentang waktu kurang dari enam bulan dapat diberikan vaksin kedua dengan jenis vaksin yang berbeda sesuai ketersediaan di masing-masing daerah

b. Bagi sasaran yang mengalami drop out dalam waktu lebih dari enam bulan, maka vaksinasi primer nya dilanjutkan kembali sebanyak 2 kali dan vaksinasi dapat menggunakan jenis vaksin yang berbeda dari vaksin semula

c. Mengingat saat ini vaksin Sinovac yang didistribusikan jumlahnya terbatas dan diperuntukkan bagi sasaran anak usia 6-11 tahun, maka sasaran yang drop out dapat menggunakan vaksin dengan jenis yang berbeda dan tersedia untuk melengkapi dosis keduanya dengan mengutamakan vaksin yang memiliki masa kadaluarsa terdekat

Segera lengkapi dosis booster dengan datang ke fasilitas kesehatan terdekat. Cek fasilitas kesehatan terdekat pada tautan https://covid19.go.id/faskesvaksin.

Data Kementerian Kesehatan menunjukkan bahwa 70% dari 8.230 pasien meninggal akibat COVID-19 belum menerima vaksinasi lengkap.

Ini membuktikan bahwa vaksinasi lengkap dan booster mampu mengurangi risiko dirawat dan kematian. Yuk, lindungi diri kita dan orang-orang di sekitar kita, segera vaksinasi jika giliran kita sudah tiba.

Vaksinasi booster dapat meningkatkan imunitas hingga 2x lipat dibanding vaksinasi dosis kedua.

Booster dapat melindungi orang tua dan kelompok masyarakat rentan/memiliki komorbid dari penularan COVID-19.

Saat ini stok vaksin COVID-19 untuk booster lebih dari cukup, ayo segerakan dapat booster jika gilirannya sudah tiba.

Vaksin booster gratis untuk semua Warga Negara Indonesia.

sumber: Kemenkes

Anda bisa mendapatkan vaksin booster setelah 3 bulan mendapatkan vaksin dosis kedua. Jadwal dan tiket vaksinasi akan muncul di aplikasi PeduliLindungi pada menu “Status Vaksinasi & Hasil Tes Covid-19”.

sumber: Kemenkes

Info Penting